A Phase 4 interventional study of Lansoprazole/Domperidone in Gastroesophageal Reflux Disease, sponsored by Neutec Ar-Ge San ve Tic A.Ş. Completed at 1 site in Turkey. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-11-08.
Sponsored by Neutec Ar-Ge San ve Tic A.Ş · Phase 4, Interventional, and Treatment
The purpose of this study is to investigate the efficacy of lansoprazole combination with domperidone on intragastric acidity and intraesophageal acidity, GERD symptoms, impedance kinetics, gastric emptying in patients with gastroesophageal reflux disease (GERD).
Objectives of the trial to assess the efficacy of lansoprazole in combination with domperidone on gastric acidity, intraesophageal acidity, GERD symptoms, impedance kinetics and gastric emptying in patients with GERD.
24 hour pH measurement and gastric emptying test will be done at screening visit and after 7 days of drug treatment. Twelve patients will take one tablet for 7 days.
1,067 studies on the registry are indexed under Gastroesophageal Reflux; 188 are open to participants now.
This study's enrollment of 12 is below the median of 72 across 712 interventional studies indexed under Gastroesophageal Reflux.
Browse Gastroesophageal Reflux studies →Neutec Ar-Ge San ve Tic A.Ş is the lead sponsor of 20 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
DUOLANS 30/30 mg SR tablet per oral, one tablet daily
Drug: Lansoprazole/Domperidone
DUOLANS 30/30 mg SR tablet per oral, one tablet daily
Also known as: Duolans
The percentage time of 24-hour intragastric pH >4 compared to baseline
Time frame: 7 days
The AUC of 24-hour intragastric pH >4 compared to baseline
Time frame: 7 days
The significant increase in total measurements of median pH
Time frame: 7 days
The significant increase in nocturnal measurements of median pH
Time frame: 7 days
The decrease in reflux symptom index calculated by weekly regurgitation numbers
Time frame: 7 days
The decrease in reflux symptom index calculated by weekly pyrosis numbers
Time frame: 7 days
The percentage time of 24-hour intragastric pH >2 compared to baseline
Time frame: 7 days
The percentage time of 24-hour intragastric pH >6 compared to baseline
Time frame: 7 days
The AUC of 24-hour intragastric pH >2 compared to baseline
Time frame: 7 days
The AUC of 24-hour intragastric pH >6 compared to baseline
Time frame: 7 days
The percentage time of 24-hour total intragastric pH >4 compared to baseline
Time frame: 7 days
The AUC of 24-hour total intragastric pH >4 compared to baseline
Time frame: 7 days
The evaluation of gastric emptying by octanoic acid breath test compared to baseline
Time frame: 7 days
The evaluation of safety of study drug (Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment)
Time frame: 7 days
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neutec Ar-Ge San ve Tic A.Ş